61 results about "Hormone therapy" patented technology

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and / or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and / or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

The present invention provides a traditional Chinese medicine preparation for treating importence, which is the prepared slice comprising the following medicinal materials: 20-180 parts by weight of Astragalus root; 15-30 parts by weight of Chinese angelica; 15-30 parts by weight of pilose asiabell root or 15-20 parts by weight of ginseng; 15-30 parts by weight of white peony root; 6-15 parts by weight of actynolin; 2-3 parts by weight of centipede; 10-15 parts by weight of shorthorned epimedium herb; 10-15 parts by weight of dodder seed; 15-30 parts by weight of common cnidium fruit; 6-15 parts by weight of chuanxiong rhizome; 6-15 parts by weight of nutgrass galingale rhizome; 3-5 parts by weight of powdered antler or 0.5-1.5 parts by weight of hairy antler; and 6-10 parts by weight of liquorice. The Chinese medicine preparation for treating importenance according to the invention applies the method of general nourishment on the basis of the theory of traditional Chinese medicine forregulating the dysfunction of meridian of human organ and the unsmooth running of qi-blood and body fluid. The invention overcomes the defect of unremarkable effect when the method of temperature compensation is singly applied for treating the asynodia according to the traditional Chinese medicine. Simultaneously the side effect caused by singly adopting vasodilation or hormone therapy accordingto the western medicine. The traditional Chinese medicine of the invention has the characteristics of quick curative effect, no toxic or side effect, flexible theory and radical treatment. Simultaneously according to the principle of treating the root of the disease in the theory of traditional Chinese medicine, the medicine is added or reduced according to the illness state on the basis of general nourishment for adopting the symptoms of different patients or the illness states of a same patient in different periods.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and / or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.

The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.